CClinicalTrials.gg
WithdrawnNCT05753085MOUSAUpdated Sep 17, 2025

Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment

An interventional study of Conavi Medical Novasight Hybrid System intervention in Coronary Artery Disease, Coronary Stenosis and Plaque, Atherosclerotic, sponsored by Barts & The London NHS Trust. Withdrawn at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Barts & The London NHS Trust · Not applicable, Interventional, and Diagnostic

Why this study was withdrawn
Concerns with capacity
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This investigation is to see if the new Novasight Hybrid imaging catheter can safely and accurately provide two different types of images (IVUS and OCT) of the inside of heart vessels at the same time. The images will be compared against one type of image (IVUS) to see if providing two, improves identification of different types of plaque (fatty substances) and informs better treatment.

Atherosclerotic coronary artery disease is the name given to the development of plaques in the heart vessels. The plaques can cause narrowing in the vessels which may cause chest pain. Sometimes, plaques completely block the vessels causing a heart attack. This type of disease is the main cause of death worldwide.

Research shows that when the type of plaque causing problems is known, it can help understanding of which narrowing may get worse and cause a heart attack. This information can also help with deciding when and which treatment to provide.

Intravascular imaging is a way to assess the inside of the heart arteries. It involves passing a narrow catheter into the heart vessels. The catheter has a probe on its tip that emits light or an ultrasound signal. The signal is reflected by the vessel wall, back into the probe. A computer program interprets the signals and creates images of the inside of the arteries. There are two types of imaging catheters. One uses sound (Intravascular Ultrasound (IVUS)) and one uses light ((OCT) Optical Coherence Tomography) to produce different types of pictures of the vessels and plaques. The images produced by each type do not provide a full picture of the plaques on their own.

A new hybrid imaging catheter has been developed which has two probes at the tip, an IVUS probe and an OCT probe and can produce both types of images at the same time. It is likely that having both types of images is better for finding high-risk plaques and should lead to better, more specific treatment.

50 heart attack patients who need an angiogram will have images of their vessels taken during their treatment. Once the imaging is complete the patient will continue with their routine planned care.

The information from the images will be used to see how safe and accurate this new hybrid catheter is compared with the separate IVUS and OCT catheters, and also check to see if it is easier to identify plaques that might cause future problems. The study also aims to develop new ways to process and use the images from the hybrid catheter to better treat the plaques that cause the heart attack.

02

Conditions studied

  • Coronary Artery Disease
  • Coronary Stenosis
  • Plaque, Atherosclerotic

Keywords

  • Coronary
  • Intravascular Imaging
  • Plaque
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

Browse Coronary Artery Disease studies →

Lead sponsor

Barts & The London NHS Trust is the lead sponsor of 149 studies on the registry; 21 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

General Inclusion Criteria

  1. Age ≥ 18 to ≤80 years
  2. Patient has capacity and willing to consent
  3. Must be able to understand English language adequately
  4. Patient admitted with an NSTEMI listed for coronary angiography

Angiographic Inclusion Criteria 1) Culprit lesion amenable to PCI

Exclusion criteria

Exclusion Criteria:

General exclusion criteria:

  1. eGFR \<45ml/min/1.73m²,
  2. No known conditions with anticipated life expectancy \<1 year,
  3. History of heart transplantation,
  4. History of Coronary Artery Bypass Grafts (CABG )
  5. Intravenous contrast allergy or inability to receive treatment with aspirin, heparin, or thienopyridines,
  6. Pregnant or lactating women
  7. Decompensated heart failure, or known left ventricular ejection fraction ≤30%

Angiographic exclusion criteria:

  1. TIMI 0 flow distally to the culprit lesion,
  2. The culprit lesion is located in the left main stem or the ostium of the right coronary artery,
  3. Patient that requires surgical revascularization,
  4. Unfavourable anatomy for intravascular imaging (i.e., the culprit lesion is a chronic total occlusion or is located in a tortuous vessel where intravascular imaging is not feasible)

Intraprocedural exclusion criteria:

1) If the patient demonstrates evidence of active ischemia or hemodynamic compromise of concern to the operator prior to first insertion of the imaging device (e.g., such as a complication caused by wiring the lesion or after pre-dilating prior to advancing the imaging device for the first time) the study procedure should not commence.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Conavi Medical Novasight Hybrid System intervention

    Patients who present with non-ST elevation myocardial infarction (NSTEMI) and require an angiogram and or PCI will have intravascular imaging assessment of the culprit vessel using the Conavi Medical Hybrid System (Novasight Hybrid Catheter, Novasight Hybrid PIM, Novasight Hybrid Hummingbird Console)

    Device: Conavi Medical Novasight Hybrid System intervention

Interventions

  • DeviceConavi Medical Novasight Hybrid System intervention

    Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care

    Also known as: IVUS & OCT

06

What researchers measure

Primary outcomes

  1. To assess the superiority of IVUS-OCT over standalone IVUS in guiding PCI

    The number of post PCI findings associated with worse outcomes (i.e., stent un-der expansion, major malappositions, major dissections, large thrombus burden and residual plaque at the edges of the stent) detected by the Conavi Medical Hybrid Imaging System and stand alone IVUS

    Time frame: Measured at procedure

Secondary outcomes

  1. To examine the safety of the IVUS- OCT catheter in patients undergoing angiography and IVUS-OCT assessment

    The number of device related complications (vessel perforation, dissection and acute vessel closure during or following IVUS-OCT imaging).

    Time frame: Measured at procedure, at 1 week post procedure, at 1 month post procedure and 12 months post procedure

  2. To examine the safety of the IVUS- OCT imaging procedure

    The number of procedural complications defined as: vessel perforation, angiographic dissection, stent thrombosis, thrombus embolization and acute vessel closure.

    Time frame: Measured at procedure, at 1 week post procedure, at 1 month post procedure and 12 months post procedure

  3. To examine the safety of the IVUS- OCT catheter in patients undergoing angiography and intravascular imaging

    The number of participant deaths or myocardial infarctions

    Time frame: Measured at procedure, at 1 week post procedure, at 1 month post procedure and 12 months post procedure

07

Study locations

1 site
  • St Bartholomew's Hospital
    London, England EC1A 7BE, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05753085
Lead sponsor
Barts & The London NHS Trust
Collaborators
Rosetrees Trust, National Institute for Health Research, United Kingdom, Conavi Medical Inc
Responsible party
Sponsor
First posted
Mar 3, 2023
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Christos Bourantas
principal investigator · Barts & The London NHS Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion